AKTRES study: A Biologic Study of the early effects and determinants of AKT inhibition using GSK2110183 alongside chemotherapy in patients with Platinum RESistant Adenocarcinoma of the ovary

As part of the main study, patients will initially undergo certain tests and scans to make sure that the study is right for them. During this time, three extra 10ml tubes of blood (30ml, 6-8 teaspoons) will be taken for this sub-study. During routine blood tests before each cycle of chemotherapy and maintenance phase of the GSK2110183 drug (see main study details below), an extra 30mls of blood will be collected. At the end of the study, a final 30mls of blood will also be collected. Patients will also be asked to have a biopsy of their tumour before starting treatment (chemotherapy) and during treatment. The biopsies will give the researchers information about how the drug works and help to develop tests that predict who might respond to treatment. The tests involve looking at the molecules in the tumour tissue. Biopsies will be done only if it is easy to perform with minimal discomfort to participants. This will be done as a day case at the hospital after using a local numbing medicine to allow painless biopsy from the area by an experienced radiologist. The second biopsy is optional. Addditionally, at any point during the study, should a participant require a clinical procedure to remove fluid from their abdomen, researchers would like to store some of the fluid which would otherwise be disposed of. To see details of the main study please go to; http://www.clinicaltrials.gov/ct2/show/NCT01653912?term=NCT01653912&rank=1